

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 35 returned.**☐ 1. Document ID: US 20030082187 A1

L3: Entry 1 of 35

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082187

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082187 A1

TITLE: Combined cancer treatment methods using antibodies to aminophospholipids

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Ran, Sophia	Dallas	TX	US	

US-CL-CURRENT: 424/155.1

ABSTRACT:

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNIC
Draw Desc	Image										

☐ 2. Document ID: US 20030082106 A1

L3: Entry 2 of 35

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082106

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082106 A1

TITLE: Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nivorozhkin, Aleksandr	West Roxbury	MA	US	
McMurry, Thomas J.	Winchester	MA	US	
Kolodziej, Andrew	Winchester	MA	US	

US-CL-CURRENT: 424/9.34; 530/324

ABSTRACT:

The present invention relates to contrast agents for diagnostic magnetic resonance imaging. In particular, this invention relates to novel compounds which exhibit surprisingly improved relaxivity due to improved binding of an amino acid targeting group within the molecules to proteins following specific cleavage of the agent by a peptidase. This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for contrast enhancement during magnetic resonance imaging.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw	Desc	Image							

KMC

☐ 3. Document ID: US 20030077809 A1

L3: Entry 3 of 35

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077809

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077809 A1

TITLE: 97 human secreted proteins

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Florence, Kimberly	Rockville	MD	US	
Ni, Jian	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	
Moore, Paul A.	Germantown	MD	US	
Olsen, Henrik	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Young, Paul	Gaithersburg	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Brewer, Laurie A.	St. Paul	MN	US	
Soppet, Daniel R.	Centreville	CA	US	
LaFleur, David W.	Washington	DC	US	
Endress, Gregory A.	Potomac	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 4. Document ID: US 20030044871 A1

L3: Entry 4 of 35

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044871
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044871 A1

TITLE: Coagulation assay reagents containing lanthanides and a protein C assay using such a lanthanide-containing reagent

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cutsforth, Gwyn A.	Chapel Hill	NC	US	
Mahan, Donald E.	Raleigh	NC	US	

US-CL-CURRENT: 435/13; 435/214

ABSTRACT:

A method, kit, system and reagent for performing coagulation assays with higher sensitivity and greater dynamic range is provided which involves the use of one or more metal compounds that interact with calcium binding sites in the blood coagulation cascade, particularly lanthanide compounds, manganese compounds and magnesium compounds. A Protein C reagent, kit, and assay method is also provided using the same type of metal compounds to provide greater detection sensitivity and dynamic range between samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 5. Document ID: US 20030027235 A1

L3: Entry 5 of 35

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027235
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027235 A1

TITLE: Novel method and diagnostic agent for hemostasis diagnosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kraus, Michael	Marburg		DE	
Schelp, Carsten	Marburg		DE	
Wiegand, Andreas	Schwalmstadt		DE	

US-CL-CURRENT: 435/13

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 6. Document ID: US 20030012789 A1

L3: Entry 6 of 35

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012789

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030012789 A1

TITLE: Receptor specific transepithelial transport of therapeutics

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	

US-CL-CURRENT: 424/145.1; 424/155.1, 424/178.1, 424/45

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 7. Document ID: US 20020192688 A1

L3: Entry 7 of 35

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192688
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192688 A1

TITLE: Imaging nucleic acid delivery

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yang, Xiaoming	Baltimore	MD	US	
Atalar, Ergin	Columbia	MD	US	

US-CL-CURRENT: 435/6; 424/9.35, 424/93.2, 435/320.1, 435/456, 514/44

ABSTRACT:

The invention provides compositions and methods to monitor delivery of nucleic acids (e.g., such as genes) to a target cell. The compositions comprise a nucleic acid delivery vehicle and a contrast agent. Preferably, the contrast agent is suitable for use in magnetic resonance imaging (MRI). The compositions can be used to monitor the efficacy and selectivity of gene delivery. The invention also provides a medical access device for delivering compositions according to the invention to a target tissue. Preferably, the medical access device comprises a perfusion-porous nucleic acid delivery balloon catheter which can be used in an interventional vascular procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 8. Document ID: US 20020192222 A1

L3: Entry 8 of 35

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192222
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192222 A1

TITLE: Receptor specific transepithelial transport of therapeutics

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumberg, Richard S.	Chestnut Hill	MA	US	
Simister, Neil E.	Wellesley	MA	US	
Lencer, Wayne I.	Jamaica Plain	MA	US	

US-CL-CURRENT: 424/178.1; 424/155.1, 424/45

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw	Desc	Image								

☐ 9. Document ID: US 20020146371 A1

L3: Entry 9 of 35

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146371

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020146371 A1

TITLE: Methods for development and use of diagnostic and therapeutic agents

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, King Chuen	Bethesda	MD	US	
Bednarski, Mark David	Los Altos	CA	US	

US-CL-CURRENT: 424/1.73; 424/9.35, 424/9.43, 424/9.6, 435/6

ABSTRACT:

In vivo imaging of disease associated tissues, including tumors and other malignant growths, infection and inflammation, is used in the discovery, screening and development of therapeutic and/or diagnostic molecular targets for intervention in the treatment of the diseases involved. In vivo imaging is used to detect spatial and temporal variations in the imaging features of disease associated tissues. The physical regions of the tissue that correlate with imaging features are then assessed for patterns of gene expression. The corresponding genes or gene products that are upregulated in the regions of interest are useful as therapeutic and imaging targets, with enhanced spatial and/or temporal specificity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw	Desc	Image								

☐ 10. Document ID: US 20020090708 A1

L3: Entry 10 of 35

File: PGPB

Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090708

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020090708 A1

TITLE: DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lee, Tae Ho	Seoul	NY	KR	
Wisniewski, Hans Georg	New York	NY	US	
Vilcek, Jan	New York		US	

US-CL-CURRENT: 435/226; 530/351

ABSTRACT:

TSG protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 11. Document ID: US 20020086821 A1

L3: Entry 11 of 35

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086821

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086821 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.1

ABSTRACT:

The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors,

host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 12. Document ID: US 6537829 B1

L3: Entry 12 of 35

File: USPT

Mar 25, 2003

US-PAT-NO: 6537829

DOCUMENT-IDENTIFIER: US 6537829 B1

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 436/514; 250/458.1, 250/459.1, 356/244, 435/7.1, 435/7.5, 435/970, 435/973, 436/164, 436/172, 436/177, 436/518, 436/528, 436/540, 436/546, 436/800, 436/805, 436/806

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

52 Claims, 41 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 35

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 13. Document ID: US 6518401 B2

L3: Entry 13 of 35

File: USPT

Feb 11, 2003

US-PAT-NO: 6518401

DOCUMENT-IDENTIFIER: US 6518401 B2

TITLE: Tumor necrosis factor stimulated gene 6 (TSG-6) protein

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae Ho	Seoul			KR
Wisniewski; Hans-Georg	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 530/350; 530/300, 530/351, 530/402

ABSTRACT:

TSG protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

4 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KIMC

☐ 14. Document ID: US 6485726 B1

L3: Entry 14 of 35

File: USPT

Nov 26, 2002

US-PAT-NO: 6485726

DOCUMENT-IDENTIFIER: US 6485726 B1

TITLE: Receptor specific transepithelial transport of therapeutics

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blumberg; Richard S.	Chestnut Hill	MA		
Simister; Neil E.	Wellesley	MA		
Lencer; Wayne I.	Jamaica Plain	MA		

US-CL-CURRENT: 424/178.1; 424/185.1, 424/192.1, 424/193.1, 424/277.1

ABSTRACT:

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

10 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw	Desc	Image								

☐ 15. Document ID: US 6482653 B1

L3: Entry 15 of 35

File: USPT

Nov 19, 2002

US-PAT-NO: 6482653

DOCUMENT-IDENTIFIER: US 6482653 B1

TITLE: Method and diagnostic agent for hemostasis diagnosis

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kraus; Michael	Marburg			DE
Schelp; Carsten	Marburg			DE
Wiegand; Andreas	Schwalmstadt			DE

US-CL-CURRENT: 436/69; 435/13

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

6 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 16. Document ID: US 6406693 B1

L3: Entry 16 of 35

File: USPT

Jun 18, 2002

US-PAT-NO: 6406693

DOCUMENT-IDENTIFIER: US 6406693 B1

TITLE: Cancer treatment methods using antibodies to aminophospholipids

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/130.1; 424/132.1, 424/133.1, 424/135.1, 424/138.1, 424/141.1, 424/152.1, 424/184.1, 435/6, 530/387.1

ABSTRACT:

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

63 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 17. Document ID: US 6399397 B1

L3: Entry 17 of 35

File: USPT

Jun 4, 2002

US-PAT-NO: 6399397

DOCUMENT-IDENTIFIER: US 6399397 B1

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 436/518; 435/7.1, 435/7.5, 435/970, 435/973, 436/164, 436/169,
436/172, 436/177, 436/528, 436/540, 436/546, 436/800, 436/805

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

18 Claims, 44 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 35

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCC
Draw Desc	Image									

☐ 18. Document ID: US 6312914 B1

L3: Entry 18 of 35

File: USPT

Nov 6, 2001

US-PAT-NO: 6312914

DOCUMENT-IDENTIFIER: US 6312914 B1

TITLE: Up-converting reporters for biological and other assays

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kardos; Keith W.	Bethlehem	PA		
Niedbala; R. Sam	Allentown	PA		
Burton; Jarrett Lee	Allentown	PA		
Cooper; David E.	Palo Alto	CA		
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Cossonay			CH
Peppers; Norman A.	Dixon	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	Richardson	TX		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 435/6; 250/484.2, 250/484.3, 435/325, 435/5, 435/7.1, 530/350,
530/387.1, 536/24.3

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

4 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 19. Document ID: US 6312694 B1

L3: Entry 19 of 35

File: USPT

Nov 6, 2001

US-PAT-NO: 6312694

DOCUMENT-IDENTIFIER: US 6312694 B1

**** See image for Certificate of Correction ****

TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/178.1; 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/137.1,
424/141.1, 424/142.1, 424/143.1, 424/181.1, 424/193.1, 514/12, 530/387.1, 530/388.1

ABSTRACT:

Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

50 Claims, 6 Drawing figures
Exemplary Claim Number: 1,2,3,4
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 20. Document ID: US 6210905 B1

L3: Entry 20 of 35

File: USPT

Apr 3, 2001

US-PAT-NO: 6210905

DOCUMENT-IDENTIFIER: US 6210905 B1

TITLE: Tumor necrosis factor stimulated gene 6 (TSG-6) binding molecules

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae Ho	Seoul			KR
Wisniewski; Hans-Georg	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 435/7.1; 436/501, 530/387.1, 530/388.1

ABSTRACT:

TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

5 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

[Generate Collection](#)[Print](#)

Term	Documents
MAGNET\$	0
MAGNET.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	311293
MAGNETA.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	908
MAGNETABILITY.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETABLE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	10
MAGNETABLY.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETABRASIVE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	4
MAGNETACOUSTIC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACRYSTALLINE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACTIC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACTUATED.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
(L2 AND MAGNET\$).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	35

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 35 of 35 returned.**☐ 21. Document ID: US 6187594 B1

L3: Entry 21 of 35

File: USPT

Feb 13, 2001

US-PAT-NO: 6187594

DOCUMENT-IDENTIFIER: US 6187594 B1

**** See image for Certificate of Correction ****

TITLE: Method and diagnostic agent for hemostasis diagnosis

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kraus; Michael	Marburg			DE
Schelp; Carsten	Marburg			DE
Wiegand; Andreas	Schwalmstadt			DE

US-CL-CURRENT: 436/69; 422/52, 422/73, 436/172

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

55 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[RWC](#)☐ 22. Document ID: US 6159686 A

L3: Entry 22 of 35

File: USPT

Dec 12, 2000

US-PAT-NO: 6159686

DOCUMENT-IDENTIFIER: US 6159686 A

TITLE: Up-converting reporters for biological and other assays

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kardos; Keith W.	Bethlehem	PA		
Niedbala; R. Sam	Allentown	PA		
Burton; Jarrett Lee	Allentown	PA		
Cooper; David E.	Palo Alto	CA		
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Cossonay			CH
Peppers; Norman A.	Dixon	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	Richardson	TX		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 435/6; 250/484.2, 250/484.3, 435/5, 435/7.1, 530/350, 530/387.1,
536/23.1, 536/24.3

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

19 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 23. Document ID: US 6132965 A

L3: Entry 23 of 35

File: USPT

Oct 17, 2000

US-PAT-NO: 6132965

DOCUMENT-IDENTIFIER: US 6132965 A

TITLE: Methods and compositions for diagnosis of hyperhomocysteinemia

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Austin; Richard C.	Ancaster			CA
Hirsh; Jack	Hamilton			CA
Weitz; Jeffrey I.	Hamilton			CA

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

3 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 24. Document ID: US 5891656 A

L3: Entry 24 of 35

File: USPT

Apr 6, 1999

US-PAT-NO: 5891656
DOCUMENT-IDENTIFIER: US 5891656 A

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 435/7.92; 422/56, 422/82.08, 435/7.21

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

6 Claims, 41 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 32

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 25. Document ID: US 5846763 A

L3: Entry 25 of 35

File: USPT

Dec 8, 1998

US-PAT-NO: 5846763

DOCUMENT-IDENTIFIER: US 5846763 A

TITLE: DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae Ho	Daejeon			KR
Wisniewski; Hans-Georg	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.1, 536/23.5

ABSTRACT:

TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

14 Claims, 48 Drawing figures

Exemplary Claim Number: 2

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 26. Document ID: US 5817461 A

L3: Entry 26 of 35

File: USPT

Oct 6, 1998

US-PAT-NO: 5817461

DOCUMENT-IDENTIFIER: US 5817461 A

TITLE: Methods and compositions for diagnosis of hyperhomocysteinemia

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Austin; Richard C.	Ancaster			CA
Hirsh; Jack	Hamilton			CA
Weitz; Jeffrey I.	Hamilton			CA

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

5 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 27. Document ID: US 5736410 A

L3: Entry 27 of 35

File: USPT

Apr 7, 1998

US-PAT-NO: 5736410

DOCUMENT-IDENTIFIER: US 5736410 A

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: April 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 436/172; 250/458.1, 250/459.1, 356/244, 356/318, 356/417, 422/81, 422/82.05, 422/82.09, 436/518, 436/52, 436/524, 436/63, 436/81

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

23 Claims, 44 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 35

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 28. Document ID: US 5698397 A

L3: Entry 28 of 35

File: USPT

Dec 16, 1997

US-PAT-NO: 5698397

DOCUMENT-IDENTIFIER: US 5698397 A

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: December 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: 435/6; 216/25, 250/581, 313/467, 435/5, 435/7.1, 536/24.3

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

11 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 29. Document ID: US 5686478 A

L3: Entry 29 of 35

File: USPT

Nov 11, 1997

US-PAT-NO: 5686478

DOCUMENT-IDENTIFIER: US 5686478 A

TITLE: Endothelin antagonists

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Greenlee; William J.	Teaneck	NJ		
Walsh; Thomas F.	Westfield	NJ		

US-CL-CURRENT: [514/382](#); [514/464](#), [514/466](#), [548/252](#), [548/253](#), [549/441](#), [549/444](#), [549/447](#)

ABSTRACT:

Novel derivatives of the general structural Formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, complications of diabetes, migraine, bone resorption, and inflammatory diseases, including Raynaud's disease and asthma.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 30. Document ID: US 5674698 A

L3: Entry 30 of 35

File: USPT

Oct 7, 1997

US-PAT-NO: 5674698

DOCUMENT-IDENTIFIER: US 5674698 A

TITLE: Up-converting reporters for biological and other assays using laser excitation techniques

DATE-ISSUED: October 7, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zarling; David A.	Menlo Park	CA		
Rossi; Michel J.	Lausanne			CH
Peppers; Norman A.	Belmont	CA		
Kane; James	Lawrenceville	NJ		
Faris; Gregory W.	Menlo Park	CA		
Dyer; Mark J.	San Jose	CA		
Ng; Steve Y.	San Francisco	CA		
Schneider; Luke V.	Half Moon Bay	CA		

US-CL-CURRENT: [435/7.92](#); [422/52](#), [422/56](#), [422/82.05](#), [435/7.1](#), [435/7.95](#), [436/169](#), [436/172](#)

ABSTRACT:

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and

apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

36 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 31. Document ID: US 5670479 A

L3: Entry 31 of 35

File: USPT

Sep 23, 1997

US-PAT-NO: 5670479
DOCUMENT-IDENTIFIER: US 5670479 A

TITLE: .alpha.-ketoamide derivatives as inhibitors of thrombosis

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abelman; Matthew M.	Solana Beach	CA		
Pearson; Daniel A.	Bedford	NH		
Vlasuk; George P.	Carlsbad	CA		
Webb; Thomas R.	Encinitas	CA		

US-CL-CURRENT: 514/12; 424/1.69, 424/9.341, 514/13, 530/324, 530/325, 530/326

ABSTRACT:

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described.

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition characterized by thrombosis and methods of in vivo imaging of thrombi in a mammal are also disclosed.

60 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 32. Document ID: US 5656600 A

L3: Entry 32 of 35

File: USPT

Aug 12, 1997

US-PAT-NO: 5656600
DOCUMENT-IDENTIFIER: US 5656600 A

TITLE: .alpha.-ketoamide derivatives as inhibitors of thrombosis

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abelman; Matthew M.	Solana Beach	CA		
Pearson; Daniel A.	Solana Beach	CA		
Vlasuk; George P.	Carlsbad	CA		
Webb; Thomas R.	Encinitas	CA		

US-CL-CURRENT: 514/13; 424/1.69, 424/9.341, 514/12, 530/324, 530/325, 530/326

ABSTRACT:

.alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described.

.alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition characterized by thrombosis and methods of in vivo imaging of thrombi in a mammal are also disclosed.

81 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 33. Document ID: US 5632991 A

L3: Entry 33 of 35

File: USPT

May 27, 1997

US-PAT-NO: 5632991
DOCUMENT-IDENTIFIER: US 5632991 A
**** See image for Certificate of Correction ****

TITLE: Antibodies specific for E-selectin and the uses thereof

DATE-ISSUED: May 27, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gimbrone, Jr.; Michael A.	Jamaica Plain	MA		

US-CL-CURRENT: 424/178.1; 424/143.1, 424/172.1, 530/391.7, 530/395

ABSTRACT:

A method is provided for selectively targeting a therapeutic agent to a site of activated endothelium by administering a pharmaceutical composition comprising a therapeutically effective amount of an E-selectin (formerly called ELAM-1) specific monoclonal antibody conjugated to a therapeutic agent. An immunoconjugate comprising an E-selectin specific monoclonal antibody and a therapeutic agent is also provided. A method is also provided for the treatment of a vascular smooth muscle cell proliferative disorder, vasculitis, inflammation, post-reperfusion injury, microbial infections, acute or chronic allograft rejection, and leukemia, as well as for the inhibition of metastatic spread of tumor cells, by administering a pharmaceutical composition comprising a therapeutically effective amount of an E-selectin antibody, or antibody fragment, either alone, or conjugated to a therapeutic agent.

15 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KOMC
Draw Desc	Image									

☐ 34. Document ID: US 5426181 A

L3: Entry 34 of 35

File: USPT

Jun 20, 1995

US-PAT-NO: 5426181
DOCUMENT-IDENTIFIER: US 5426181 A

TITLE: DNA encoding cytokine-induced protein, TSG-14

DATE-ISSUED: June 20, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae H.	Cambridge	MA		
Lee; Gene W.	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/69.1, 536/23.1

ABSTRACT:

Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a polypeptide molecule, termed TSG-14, in connective tissue cells. The TSG-14 polypeptide and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the polypeptide and the DNA are provided. Antibodies specific for the TSG-14 polypeptide are disclosed, as is a method for detecting the presence of TSG-14 polypeptide in a biological sample, using the antibody or another molecule capable of binding to TSG-14 such as hyaluronic acid. A method for detecting the presence of nucleic acid encoding a normal or mutant TSG-14 polypeptide, a method for measuring induction of expression of TSG-14 in a cell using either nucleic acid hybridization or immunoassay, a method for identifying a compound capable of inducing the expression of TSG-14 in a cell, and a method for measuring the ability of a cell to respond to TNF are also provided.

8 Claims, 36 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 35. Document ID: US 5386013 A

L3: Entry 35 of 35

File: USPT

Jan 31, 1995

US-PAT-NO: 5386013

DOCUMENT-IDENTIFIER: US 5386013 A

TITLE: Tumor necrosis factor-induced protein TSG-6

DATE-ISSUED: January 31, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae H.	Piscataway	NJ		
Wisniewski; Hans-Georg	Spring Valley	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 530/350; 435/69.1, 530/351

ABSTRACT:

Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a protein molecule, termed TSG-6, in connective tissue cells. The TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided. Antibodies specific for the TSG-6 protein are disclosed, as is a method for detecting the presence of TSG-6 protein in a biological sample, using the antibody or another molecule capable of binding to TSG-6 such as hyaluronic acid. A method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein, a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay, a method for identifying a compound capable of inducing the expression of TSG-6 in a cell, and a method for measuring the ability of a cell to respond to TNF are also provided.

2 Claims, 50 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

Generate Collection

Print

Term	Documents
MAGNET\$	0
MAGNET.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	311293
MAGNETA.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	908
MAGNETABILITY.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETABLE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	10
MAGNETABLY.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETABRASIVE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	4
MAGNETACOUSTIC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACRYSTALLINE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACTIC.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
MAGNETACTUATED.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1
(L2 AND MAGNET\$).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	35

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

[Previous Page](#)

[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 11 of 11 returned.**☐ 1. Document ID: US 20030044871 A1

L5: Entry 1 of 11

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044871

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044871 A1

TITLE: Coagulation assay reagents containing lanthanides and a protein C assay using such a lanthanide-containing reagent

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cutsforth, Gwyn A.	Chapel Hill	NC	US	
<u>Mahan, Donald E.</u>	Raleigh	NC	US	

US-CL-CURRENT: 435/13; 435/214

ABSTRACT:

A method, kit, system and reagent for performing coagulation assays with higher sensitivity and greater dynamic range is provided which involves the use of one or more metal compounds that interact with calcium binding sites in the blood coagulation cascade, particularly lanthanide compounds, manganese compounds and magnesium compounds. A Protein C reagent, kit, and assay method is also provided using the same type of metal compounds to provide greater detection sensitivity and dynamic range between samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KINC
Draw	Desc	Image									

☐ 2. Document ID: US D354220 S

L5: Entry 2 of 11

File: USPT

Jan 10, 1995

US-PAT-NO: D354220

DOCUMENT-IDENTIFIER: US D354220 S

TITLE: Closed disposable package

DATE-ISSUED: January 10, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mahan; Donald E.	Grafton	MA		
Kearney; Kevin R.	Worcester	MA		
Shimei; Thomas M.	Franklin	MA		
Bate; Ernest	Great Chart			GB2
Missing; Philip	Egerton			GB2
Robinson; David	Folkestone			GB2

US-CL-CURRENT: D09/341; D09/347

1 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC
Draw Desc	Image										

☐ 3. Document ID: US D354141 S

L5: Entry 3 of 11

File: USPT

Jan 3, 1995

US-PAT-NO: D354141

DOCUMENT-IDENTIFIER: US D354141 S

TITLE: Test tray

DATE-ISSUED: January 3, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bate; Ernest	Great Chart			GB2
Missing; Philip	Egerton			GB2
Robinson; David	Folkestone			GB2
Mahan; Donald E.	Grafton	MA		
Kearney; Kevin R.	Worcester	MA		
Shimei; Thomas M.	Franklin	MA		

US-CL-CURRENT: D24/227

1 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMMC
Draw Desc	Image									

☐ 4. Document ID: US 5374395 A

L5: Entry 4 of 11

File: USPT

Dec 20, 1994

US-PAT-NO: 5374395

DOCUMENT-IDENTIFIER: US 5374395 A

TITLE: Diagnostics instrument

DATE-ISSUED: December 20, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Robinson; David	Folkestone			GB2
Bate; Ernest	Great Chart			GB2
Kellard; Simon	Ashford			GB2
Watson; Mark	Ashford			GB2
Mahan; Donald E.	Grafton	MA		
Shimei; Thomas M.	Franklin	MA		
Kearney; Kevin R.	Worcester	MA		

US-CL-CURRENT: 422/64, 422/100, 422/102, 422/61, 422/63, 422/65, 422/67, 422/82.08,
435/287.2, 435/287.3, 435/288.7, 436/164, 436/165, 436/166, 436/172, 436/174,
436/180, 436/43, 436/47, 436/48, 436/49

ABSTRACT:

A dependable cost-effective clinical analyzer machine provides an efficient and easy-to-use diagnostics instrument and process to accurately, rapidly and automatically test and analyze samples in test packs for an analyte. In the clinical analyzer machine, remote-controlled trams transport test packs containing loading/unloading station to a processing/testing station via a carousel and vice versa. In the processing station, a special processor with mechanically-operated rollers mixing shoes, wastegate assembly, magnets, clamp plate and a thermal sealer, process samples in test packs with various reagents to detect an analyte. The carousel holds the test packs during incubation periods and rotates the tested disposable packs past an optical reader which optically senses the presence of an analyte in the sample. Bar code readers are provided to assist in identification of the test pack, patient and sample.

10 Claims, 50 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWWC

☐ 5. Document ID: US 4793395 A

L5: Entry 5 of 11

File: USPT

Dec 27, 1988

US-PAT-NO: 4793395

DOCUMENT-IDENTIFIER: US 4793395 A

TITLE: Tire shock absorber

DATE-ISSUED: December 27, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mahan; Donald E.	Forked River	NJ	08731	

US-CL-CURRENT: 152/8, 138/89.3, 138/89.4, 141/46, 152/337.1, 152/418, 152/428,
152/429, 152/DIG.11, 188/314, 267/64.11

ABSTRACT:

A tire shock absorber for attachment to a pneumatic tube tire or pneumatic tubeless tire for improving the smoothness of ride and decreasing road vibrations, the tire shock absorber comprising a chamber having at least one valve means which permits the unrestricted flow of air from the tubeless tire or tube tire into the chamber when the tire is subjected to intermittent road pressure, the valve means permitting the return of the displaced air to the tubeless tire or tube tire subsequent to the tire being subjected to the intermittent pressure. The tire shock absorber is designed for positioning either exterior to the tire or interior to the tire depending upon whether or not it is a tube tire or a tubeless tire.

4 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw. Desc	Image								

KUMC

☐ 6. Document ID: US 4588721 A

L5: Entry 6 of 11

File: USPT

May 13, 1986

US-PAT-NO: 4588721

DOCUMENT-IDENTIFIER: US 4588721 A

TITLE: Treatment of negative symptoms of schizophrenia

DATE-ISSUED: May 13, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mahan; Donald R.	San Jose	CA		

US-CL-CURRENT: 514/220

ABSTRACT:

Therapeutic process for treating the negative symptoms of schizophrenia in humans comprising the systematic administration of a compound of the formula ##STR1## X is a member selected from the group consisting of --H, --CH.sub.3, and --CH.sub.2 --O--R;

wherein R is hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive, ##STR2## wherein n is 0 to 16, inclusive, and m is 1 to 16 inclusive; Y is hydrogen or, provided when Z is hydrogen and X is CH.sub.3, hydroxy;

Z is hydrogen or, provided when Y is hydrogen and X is --CH.sub.3, chloro;

including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier.

18 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 7. Document ID: JP 07191042 A

L5: Entry 7 of 11

File: JPAB

Jul 28, 1995

PUB-NO: JP407191042A

DOCUMENT-IDENTIFIER: JP 07191042 A

TITLE: AUTOMATIC DIAGNOSTIC APPARATUS FOR ANALYZING SPECIMEN IN TEST PACK FOR ANALYTICAL SUBSTANCE

PUBN-DATE: July 28, 1995

INVENTOR-INFORMATION:

NAME

COUNTRY

ROBINSON, DAVID

BATE, ERNEST

KELLARD, SIMON

WATSON, MARK

MAHAN, DONALD E

SHIMEI, THOMAS M

KEARNEY, KEVIN R

INT-CL (IPC): G01 N 35/02

ABSTRACT:

PURPOSE: To analyze a test pack to be used easily with high reliability and safely, automatically, rapidly and repetitively by providing a loading station having a loading door for continuously loading and unloading a series of the test packs.

CONSTITUTION: A test pack is held in slots 410, 412 on aligned rotary racks of rotary rack plates 404, 406 of a top part and bottom part by an arcuate spring related to the rotary rack plates on the top part and bottom part and engaging the same. A spring force of the arcuate spring at the top and bottom parts holds the test pack during the rotation of the rotary rack and during reading of a read-out head 504, while the test pack is held at the same position for its own weight until it is removed by one of a drum 300 or 302. The rotary rack is driven by a servocontrol 12V DC motor driven through a rotary rack gear 414 and pinion drive spur gear.

COPYRIGHT: (C) 1995, JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 8. Document ID: EP 732408 A2

L5: Entry 8 of 11

File: EPAB

Sep 18, 1996

PUB-NO: EP000732408A2

DOCUMENT-IDENTIFIER: EP 732408 A2

TITLE: Nucleic acid probes for the detection of chlamidia trachomatis

PUBN-DATE: September 18, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
SHAH, JYOTSNA	US
BUHARIN, AMELIA	US
WILLIAMS, CHARLOTTE	US
MAHAN, DONALD	US
LANE, DAVID J	US
KING, WALTER	US

INT-CL (IPC): C12 Q 1/68; C07 H 21/04EUR-CL (EPC): C12Q001/68

ABSTRACT:

Nucleic acid probes capable of hybridizing to rRNA of Chlamydia trachomatis and not to rRNA of non-Chlamydia are described along with methods utilizing such probes for the detection of Chlamydia trachomatis in clinical samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KIMC
Draw Desc	Image									

☐ 9. Document ID: FR 2711242 A1

L5: Entry 9 of 11

File: EPAB

Apr 21, 1995

PUB-NO: FR002711242A1

DOCUMENT-IDENTIFIER: FR 2711242 A1

TITLE: Apparatus and method for automatic diagnosis, for analysing samples in multiple test tubes

PUBN-DATE: April 21, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
DAVID, ROBINSON	
ERNEST, BATE	
SIMON, KELLARD	
MARK, WATSON	
MAHAN, DONALD E	
SHIMEL, THOMAS M	
KEARNEY, KEVIN R	

INT-CL (IPC): G01 N 35/02; G01 N 33/53EUR-CL (EPC): B01L003/00; G01N035/00

ABSTRACT:

The invention relates to an apparatus for automatic diagnosis, in which remote-controlled buckets (300, 302) carry multiple test tubes containing the samples to be monitored from a loading/unloading station to a treatment/monitoring station (602) by means of a carousel (400) and vice versa in the treatment station, and a special processor (600) with rollers (614, 616), mixing shoes (620, 622), a recovery port assembly (608), magnets (606), a blocking plate (632) and a heat-sealing device (624, 626, 628) which are controlled mechanically treats the samples in the multiple

test tubes (200) with various reagents in order to detect an analyte. 

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 10. Document ID: WO 9015159 A2

L5: Entry 10 of 11

File: EPAB

Dec 13, 1990

PUB-NO: WO009015159A2

DOCUMENT-IDENTIFIER: WO 9015159 A2

TITLE: NUCLEIC ACID PROBES FOR THE DETECTION OF CHLAMYDIA TRACHOMATIS

PUBN-DATE: December 13, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
SHAH, JYOTSNA	US
BUHARIN, AMELIA	US
WILLIAMS, CHARLOTTE	US
MAHAN, DONALD	US
LANE, DAVID J	US
KING, WALTER	US

US-CL-CURRENT: 435/6; 607/139

INT-CL (IPC): C07H 21/04; C12Q 1/68

EUR-CL (EPC): C12Q001/68

ABSTRACT:

CHG DATE=19990617 STATUS=O>Nucleic acid probes capable of hydridizing to rRNA of Chlamydia trachomatis and not to rRNA of non-Chlamydia are described along with methods utilizing such probes for the detection of Chlamydia trachomatis in clinical samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 11. Document ID: EP 139460 A2

L5: Entry 11 of 11

File: EPAB

May 2, 1985

PUB-NO: EP000139460A2

DOCUMENT-IDENTIFIER: EP 139460 A2

TITLE: Benzodiazepines and their therapeutic use.

PUBN-DATE: May 2, 1985

INVENTOR-INFORMATION:

NAME	COUNTRY
MAHAN, DONALD RICHARD	

INT-CL (IPC): A61K 31/55

EUR-CL (EPC): A61K031/55

ABSTRACT:

CHG DATE=19990617 STATUS=O> For treating the negative symptoms of schizophrenia in humans, a benzodiazepine of the formula wherein X is H, CH₃, CH₂OH, alkoxymethyl, alkanoyloxymethyl or carboxyalkanoyloxymethyl, Y is H or OH and Z is H or Cl, is used.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Clip Img	Image								

[Generate Collection](#)[Print](#)

Term	Documents
MAHAN.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	1311
MAHANS	0
DONALD.DWPI,EPAB,JPAB,USPT,PGPB.	154110
DONALDS.DWPI,EPAB,JPAB,USPT,PGPB.	29
(MAHAN ADJ (DONALD.IN.)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	11
(MAHAN DONALD.IN.)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	11

Display Format: [Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 19 of 19 returned.**☐ 1. Document ID: US 20030082187 A1

L2: Entry 1 of 19

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082187

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082187 A1

TITLE: Combined cancer treatment methods using antibodies to aminophospholipids

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Ran, Sophia	Dallas	TX	US	

US-CL-CURRENT: 424/155.1

ABSTRACT:

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 20030077809 A1

L2: Entry 2 of 19

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077809

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077809 A1

TITLE: 97 human secreted proteins

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruben, Steven M.	Olney	MD	US	
Florence, Kimberly	Rockville	MD	US	
Ni, Jian	Rockville	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	
Moore, Paul A.	Germantown	MD	US	
Olsen, Henrik	Gaithersburg	MD	US	
Shi, Yanggu	Gaithersburg	MD	US	
Young, Paul	Gaithersburg	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Brewer, Laurie A.	St. Paul	MN	US	
Soppet, Daniel R.	Centreville	CA	US	
LaFleur, David W.	Washington	DC	US	
Endress, Gregory A.	Potomac	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 20030044871 A1

L2: Entry 3 of 19

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044871

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044871 A1

TITLE: Coagulation assay reagents containing lanthanides and a protein C assay using such a lanthanide-containing reagent

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cutsforth, Gwyn A.	Chapel Hill	NC	US	
Mahan, Donald E.	Raleigh	NC	US	

US-CL-CURRENT: 435/13; 435/214

ABSTRACT:

A method, kit, system and reagent for performing coagulation assays with higher

sensitivity and greater dynamic range is provided which involves the use of one or more metal compounds that interact with calcium binding sites in the blood coagulation cascade, particularly lanthanide compounds, manganese compounds and magnesium compounds. A Protein C reagent, kit, and assay method is also provided using the same type of metal compounds to provide greater detection sensitivity and dynamic range between samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 4. Document ID: US 20030027235 A1

L2: Entry 4 of 19

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027235

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027235 A1

TITLE: Novel method and diagnostic agent for hemostasis diagnosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kraus, Michael	Marburg		DE	
Schelp, Carsten	Marburg		DE	
Wiegand, Andreas	Schwalmstadt		DE	

US-CL-CURRENT: 435/13

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 5. Document ID: US 20020132370 A1

L2: Entry 5 of 19

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020132370

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020132370 A1

TITLE: Detection of a blood coagulation activity marker in a body fluid sample

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lassen, Michael Rud	Rungsted Kyst		DK	
Borris, Lars C.	Arhus C		DK	

US-CL-CURRENT: 436/512; 422/56, 435/13, 435/7.9, 436/518, 436/69

ABSTRACT:

The invention relates to a method for detecting in a body fluid sample at least one blood coagulation activity marker that reflects a blood coagulation activity of an individual. By correlating the amount or concentration of the blood coagulation activity marker present e.g. in a urine sample, it is possible to monitor the blood coagulation activity of a patient following surgery without having to obtain a blood sample from said patient.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 6. Document ID: US 20020115222 A1

L2: Entry 6 of 19

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115222
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115222 A1

TITLE: Modified erythrocyte sedimentation rate

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Spillert, Charles R.	West Orange	NJ	US	
Khalil, Marcelle	Morganville	NJ	US	

US-CL-CURRENT: 436/70; 436/69

ABSTRACT:

Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 7. Document ID: US 20020086821 A1

L2: Entry 7 of 19

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086821
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086821 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.1

ABSTRACT:

The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 8. Document ID: US 6514766 B2

L2: Entry 8 of 19

File: USPT

Feb 4, 2003

US-PAT-NO: 6514766

DOCUMENT-IDENTIFIER: US 6514766 B2

TITLE: Modified erythrocyte sedimentation rate

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Spillert; Charles R.	West Orange	NJ	07502	
Khalil; Marcelle	Morganville	NJ		

US-CL-CURRENT: 436/70; 436/69

ABSTRACT:

Methods for enhancing the value of the traditional erythrocyte sedimentation rate

(ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.

22 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWOC

☐ 9. Document ID: US 6482653 B1

L2: Entry 9 of 19

File: USPT

Nov 19, 2002

US-PAT-NO: 6482653

DOCUMENT-IDENTIFIER: US 6482653 B1

TITLE: Method and diagnostic agent for hemostasis diagnosis

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kraus; Michael	Marburg			DE
Schelp; Carsten	Marburg			DE
Wiegand; Andreas	Schwalmstadt			DE

US-CL-CURRENT: 436/69; 435/13

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

6 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWOC

☐ 10. Document ID: US 6406693 B1

L2: Entry 10 of 19

File: USPT

Jun 18, 2002

US-PAT-NO: 6406693

DOCUMENT-IDENTIFIER: US 6406693 B1

TITLE: Cancer treatment methods using antibodies to aminophospholipids

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/130.1; 424/132.1, 424/133.1, 424/135.1, 424/138.1, 424/141.1,
424/152.1, 424/184.1, 435/6, 530/387.1

ABSTRACT:

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

63 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 11. Document ID: US 6312694 B1

L2: Entry 11 of 19

File: USPT

Nov 6, 2001

US-PAT-NO: 6312694

DOCUMENT-IDENTIFIER: US 6312694 B1

**** See image for Certificate of Correction ****

TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Ran; Sophia	Dallas	TX		

US-CL-CURRENT: 424/178.1; 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/137.1,
424/141.1, 424/142.1, 424/143.1, 424/181.1, 424/193.1, 514/12, 530/387.1, 530/388.1

ABSTRACT:

Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to

aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

50 Claims, 6 Drawing figures
Exemplary Claim Number: 1,2,3,4
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 12. Document ID: US 6187594 B1

L2: Entry 12 of 19

File: USPT

Feb 13, 2001

US-PAT-NO: 6187594

DOCUMENT-IDENTIFIER: US 6187594 B1

**** See image for Certificate of Correction ****

TITLE: Method and diagnostic agent for hemostasis diagnosis

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kraus; Michael	Marburg			DE
Schelp; Carsten	Marburg			DE
Wiegand; Andreas	Schwalmstadt			DE

US-CL-CURRENT: 436/69; 422/52, 422/73, 436/172

ABSTRACT:

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

55 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 13. Document ID: US 6177059 B1

L2: Entry 13 of 19

File: USPT

Jan 23, 2001

US-PAT-NO: 6177059

DOCUMENT-IDENTIFIER: US 6177059 B1

**** See image for Certificate of Correction ****

TITLE: GPIb-lipid complex and uses thereof

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matsuda; Hiroshi	Osaka			JP
Kamide; Kaeko	Hirakata			JP
Amatsuji; Yasuo	Hirakata			JP
Imagawa; Takashi	Fukuoka			JP
Ikeda; Yasuo	Tokyo			JP
Murata; Mitsuru	Niiza			JP

US-CL-CURRENT: 424/1.21; 424/9.321, 424/9.34, 424/9.37, 424/9.5, 424/9.51, 424/9.6,
514/21, 514/7, 514/8, 530/352, 530/359, 530/381, 530/395, 530/410

ABSTRACT:

A complex comprising a lipid and a conjugate of GPIb and lipid having a functional group, and use thereof. The GPIb-lipid complex of the present invention is extremely useful as a platelet substitute, a pharmaceutical agent for the prophylaxis and treatment of angiopathy, vascular damages and thrombosis, a diagnostic for vWF deficiency and the like, a biological or medical reagent, a reagent for screening platelet aggregation suppressant or antithrombosis, and the like. The GPIb-lipid complex of the present invention is also useful as a diagnostic for finding the location of vascular lesion or thrombus formation, or a therapeutic agent therefor, since it accumulates at vascular lesions.

27 Claims, 0 Drawing figures

Exemplary Claim Number: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWMC

☐ 14. Document ID: US 6132965 A

L2: Entry 14 of 19

File: USPT

Oct 17, 2000

US-PAT-NO: 6132965

DOCUMENT-IDENTIFIER: US 6132965 A

TITLE: Methods and compositions for diagnosis of hyperhomocysteinemia

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Austin; Richard C.	Ancaster			CA
Hirsh; Jack	Hamilton			CA
Weitz; Jeffrey I.	Hamilton			CA

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

3 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 15. Document ID: US 5994076 A

L2: Entry 15 of 19

File: USPT

Nov 30, 1999

US-PAT-NO: 5994076
DOCUMENT-IDENTIFIER: US 5994076 A

TITLE: Methods of assaying differential expression

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chenchik; Alex	Palo Alto	CA		
Jokhadze; George	Mountain View	CA		
Bibilashvilli; Robert	Moscow			RU

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

Methods and compositions are provided for analyzing differences in the RNA profiles between a plurality of different physiological samples. In the subject methods, a set of a representational number of distinct gene specific primers is used to generate labeled nucleic acids from each of the different physiological samples. The labeled nucleic acids are then compared to each other and differences in the RNA profiles are determined. The subject methods find use in methods of identifying differential gene expression.

17 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 16. Document ID: US 5817461 A

L2: Entry 16 of 19

File: USPT

Oct 6, 1998

US-PAT-NO: 5817461
DOCUMENT-IDENTIFIER: US 5817461 A

TITLE: Methods and compositions for diagnosis of hyperhomocysteinemia

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Austin; Richard C.	Ancaster			CA
Hirsh; Jack	Hamilton			CA
Weitz; Jeffrey I.	Hamilton			CA

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

5 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 17. Document ID: US 5670479 A

L2: Entry 17 of 19

File: USPT

Sep 23, 1997

US-PAT-NO: 5670479

DOCUMENT-IDENTIFIER: US 5670479 A

TITLE: .alpha.-ketoamide derivatives as inhibitors of thrombosis

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abelman; Matthew M.	Solana Beach	CA		
Pearson; Daniel A.	Bedford	NH		
Vlasuk; George P.	Carlsbad	CA		
Webb; Thomas R.	Encinitas	CA		

US-CL-CURRENT: 514/12; 424/1.69, 424/9.341, 514/13, 530/324, 530/325, 530/326

ABSTRACT:

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described.

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition characterized by thrombosis and methods of in vivo imaging of thrombi in a mammal are also disclosed.

60 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 18. Document ID: US 5656600 A

L2: Entry 18 of 19

File: USPT

Aug 12, 1997

US-PAT-NO: 5656600

DOCUMENT-IDENTIFIER: US 5656600 A

TITLE: .alpha.-ketoamide derivatives as inhibitors of thrombosis

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abelman; Matthew M.	Solana Beach	CA		
Pearson; Daniel A.	Solana Beach	CA		
Vlasuk; George P.	Carlsbad	CA		
Webb; Thomas R.	Encinitas	CA		

US-CL-CURRENT: 514/13; 424/1.69, 424/9.341, 514/12, 530/324, 530/325, 530/326

ABSTRACT:

.alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described.

.alpha.-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described.

Methods of preventing or treating in a mammal a pathological condition characterized by thrombosis and methods of in vivo imaging of thrombi in a mammal are also disclosed.

81 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 19. Document ID: US 5426181 A

L2: Entry 19 of 19

File: USPT

Jun 20, 1995

US-PAT-NO: 5426181

DOCUMENT-IDENTIFIER: US 5426181 A

TITLE: DNA encoding cytokine-induced protein, TSG-14

DATE-ISSUED: June 20, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae H.	Cambridge	MA		
Lee; Gene W.	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/69.1, 536/23.1

ABSTRACT:

Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a polypeptide molecule, termed TSG-14, in connective tissue cells. The TSG-14 polypeptide and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the polypeptide and the DNA are provided. Antibodies specific for the TSG-14 polypeptide are disclosed, as is a method for detecting the presence of TSG-14 polypeptide in a biological sample, using the antibody or another molecule capable of binding to TSG-14 such as hyaluronic acid. A method for detecting the presence of nucleic acid encoding a normal or mutant TSG-14 polypeptide, a method for measuring induction of expression of TSG-14 in a cell using either nucleic acid hybridization or immunoassay, a method for identifying a compound capable of inducing the expression of TSG-14 in a cell, and a method for measuring the ability of a cell to respond to TNF are also provided.

8 Claims, 36 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KVMC

[Generate Collection](#)[Print](#)

Term	Documents
LANTHANIDE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	11824
LANTHANIDES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	5096
CERIUM.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	35639
CERIUMS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	5
CERIA.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	4024
CERIAS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	10
PRASEODYMIUM.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	7253
PRASEODYMIUMS	0
PRASEODYMIA.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	105
PRASEODYMIAS	0
NEODYMIUM.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	17874
(L1 AND (LANTHANIDE OR CERIUM OR PRASEODYMIUM OR NEODYMIUM OR PROMETHIUM OR SAMARIUM OR EUROPIUM OR GADOLINIUM OR TERBIUM OR DYSPROSIUM OR HOLMIUM OR ERBIUM OR THULIUM OR YTTERBIUM OR LUTETIUM)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	19

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

-

[Change Format](#)

[Previous Page](#)

[Next Page](#)

WEST

Number of documents to display is limited to 10 for FULL format

Generate Collection

Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: FR 2689640 A1

L1: Entry 1 of 2

File: EPAB

Oct 8, 1993

PUB-NO: FR002689640A1

DOCUMENT-IDENTIFIER: FR 2689640 A1

TITLE: Measuring protein C or S activity in plasma - by activation with thrombomodulin and determin. of its effect on endogenous thrombin formation, esp. for assessing risk of thrombosis

PUBN-DATE: October 8, 1993

INVENTOR-INFORMATION:

NAME

COUNTRY

RENE, PITTET JEAN-LOUIS

HENRIETTE, AIACH MARTINE GENEVI

ASSIGNEE-INFORMATION:

NAME

COUNTRY

BIO MERIEUX

FR

APPL-NO: FR09204184

APPL-DATE: April 6, 1992

PRIORITY-DATA: FR09204184A (April 6, 1992)

INT-CL (IPC): G01N 33/52

EUR-CL (EPC): C12Q001/56

ABSTRACT:

Determin. of protein C and/or S in a plasma sample comprises: a) preparing a mixt. of: (i) plasma sample; (ii) a predetermined quantity of thrombomodulin; (iii) at least one activated coagulation factor and/or at least one coagulation factor activator to allow the formation of endogenous thrombin; b) incubating the obtd. mixt. in conditions allowing activation of protein C and expression of activated protein C; c) adding a thrombin substrate to the mixt.; and d) quantifying the protein C and/or S activity in the sample by the determin. of enzyme activity of the thrombin on the substrate. Pref. the mixt. is incubated for 3-6 (5) minutes at 37 deg. C. The thrombomodulin may be human or animal, natural or recombinant, and/or modified, esp. by an enzyme such as chondroitinase, trypsin, elastase or analogues, and is pref. soluble. The activated coagulation factors are pref. activated factors XII and/or X. The substrate is pref. fibrinogen. ADVANTAGE - A simple, easily automated, sensitive process which does not require the use of an exogenous activator and can be used even for low concns. of proteins C and/or S.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: FR 2689640 A1

L1: Entry 2 of 2

File: DWPI

Oct 8, 1993

DERWENT-ACC-NO: 1993-379548
DERWENT-WEEK: 199348
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Measuring protein C or S activity in plasma - by activation with thrombomodulin and determin. of its effect on endogenous thrombin formation; esp. for assessing risk of thrombosis

INVENTOR: AIACH, M G H; PITTET, J R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

BIO MERIEUX

INMR

PRIORITY-DATA: 1992FR-0004184 (April 6, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2689640 A1	October 8, 1993		021	G01N033/52

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
FR 2689640A1	April 6, 1992	1992FR-0004184	

INT-CL (IPC): G01N 33/52

ABSTRACTED-PUB-NO: FR 2689640A
BASIC-ABSTRACT:

Determin. of protein C and/or S in a plasma sample comprises:

a) preparing a mixt. of:

(i) plasma sample;

(ii) a predetermined quantity of thrombomodulin;

(iii) at least one activated coagulation factor and/or at least one coagulation factor activator to allow the formation of endogenous thrombin;

b) incubating the obtd. mixt. in conditions allowing activation of protein C and expression of activated protein C;

c) adding a thrombin substrate to the mixt.;

and d) quantifying the protein C and/or S activity in the sample by the determin. of enzyme activity of the thrombin on the substrate.

Pref. the mixt. is incubated for 3-6 (5) minutes at 37 deg. C.

The thrombomodulin may be human or animal, natural or recombinant, and/or modified, esp. by an enzyme such as chondroitinase, trypsin, elastase or analogues, and is pref. soluble.

The activated coagulation factors are pref. activated factors XII and/or X. The substrate is pref. fibrinogen.

ADVANTAGE - A simple, easily automated, sensitive process which does not require the use of an exogenous activator and can be used even for low concns. of proteins C and/or S.

CHOSEN-DRAWING: Dwg.0/1

TITLE-TERMS: MEASURE PROTEIN ACTIVE PLASMA ACTIVATE THROMBOMODULIN DETERMINE EFFECT
ENDOGENOUS THROMBIN FORMATION ASSESS RISK THROMBOSIS

DERWENT-CLASS: B04 D16 J04 S03

CPI-CODES: B04-B04A6; B04-B04D3; B04-B04D4; B11-C08E3; B12-K04A2; D05-A02C; D05-H09;
J04-C02;

EPI-CODES: S03-E14H1;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M750 M903 N102 Q233 Q435 V752

Chemical Indexing M1 *02*

Fragmentation Code

M423 M760 M903 N102 Q233 Q435 V600 V614

Chemical Indexing M1 *03*

Fragmentation Code

M423 M781 M903 N102 P831 Q233 Q435 V600 V613

Chemical Indexing M6 *04*

Fragmentation Code

M903 P813 P831 Q233 Q435 R515 R520 R521 R611 R624
R627 R637

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1993-168407

Non-CPI Secondary Accession Numbers: N1993-293156

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Clip Img	Image									

Generate Collection

Print

Terms	Documents
fr-2689640\$.did.	2

Display Format: **FULL** Change Format

[Previous Page](#)

[Next Page](#)